Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease - Takeaways - MDSpire

Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease

  • By

  • Emily C L Wong

  • Parambir S Dulai

  • John K Marshall

  • Vipul Jairath

  • Walter Reinisch

  • Neeraj Narula

  • January 13, 2025

  • 0 min

Share

  • 1

    Ustekinumab responders in ulcerative colitis had significantly higher baseline eosinophil counts compared to non-responders.

  • 2

    By week 8, ustekinumab responders showed a greater decline in eosinophil counts than non-responders.

  • 3

    In Crohn's disease, ustekinumab responders also exhibited higher baseline eosinophil counts and significant reductions by week 8.

  • 4

    No significant differences in eosinophil counts were observed among patients treated with adalimumab or vedolizumab.

  • 5

    Eosinophil reduction is a marker for early response to ustekinumab in inflammatory bowel disease.

Original Source(s)

Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease

  • by Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula

  • January 13, 2025

Related Content

Assessment of the quality and dependability of Crohn's disease-related information on Douyin and Xiaohongshu: Insights from user feedback in a cross-sectional analysis

Creation and assessment of a predictive model utilizing choroid plexus imaging from brain MRI for evaluating anti-TNF-α treatment responses in Crohn’s disease

Metabolic and Structural Alterations Linked to Mice's Vulnerability to Primary Echinostoma caproni Infections